Submission of Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx reported strong consolidated results for Q3 FY26, with revenue from operations surging to Rs 5,034.73 lakhs from Rs 2,539.25 lakhs in Q3 FY25, nearly doubling year-on-year. Consolidated profit after tax for the quarter stood at Rs 2,244.29 lakhs (vs Rs 1,349.52 lakhs YoY), with EPS of Rs 26.19. For the nine months ended December 31, 2025, consolidated revenue rose about 44% to Rs 10,648.40 lakhs and consolidated PAT grew roughly 26% to Rs 5,012.50 lakhs. The growth was driven mainly by the molecular diagnostic kits segment, which includes the newly acquired CORIS subsidiary (contributing Rs 2,400.70 lakhs in sales and Rs 700.10 lakhs profit in Q3 alone). Standalone performance was more modest, with 9M revenue of Rs 7,264.49 lakhs and PAT of Rs 4,187.04 lakhs. The auditor issued a clean limited review report with no qualifications or adverse remarks.
Strong consolidated earnings, boosted by the CORIS acquisition, signal healthy top-line and bottom-line growth for shareholders. The significant jump in diagnostic segment revenue and EPS growth of over 26% on a consolidated basis are positives, while the seasonal agrochemical business showed a slight standalone dip quarter-on-quarter.